CION Ameerpet
Pins and needles in the fingertips, numb toes, a burning that arrives at night — this is one of the most common effects of ovarian cancer chemotherapy, and one of the most under-reported. It is nerve irritation from the treatment, not the cancer spreading. Most of it settles after treatment ends, but how much settles depends heavily on decisions taken while you are still having cycles.
If you have typed chemo induced neuropathy ovarian into a search box somewhere between cycle three and cycle four, you already know the sensation this page is about: fingertips that feel wrapped in cloth, toes that tingle, a burning that turns up when the house goes quiet. It has a name — chemotherapy-induced peripheral neuropathy — and it is one of the most common effects of treatment for ovarian cancer. It is not the cancer moving into your nerves, and it is not a sign that treatment is failing.
First-line ovarian cancer chemotherapy pairs a platinum-class drug with a taxane-class drug, and both are hard on peripheral nerves in different ways. The taxane class disrupts the internal scaffolding that carries supplies from the nerve cell down the length of the fibre. The platinum class accumulates in the sensory nerve cell bodies that sit in clusters just outside the spine. Give them together, as standard treatment does, and the effects add up.
The nerves that reach the fingers and toes are the longest in the body, so they run short of supplies first. That is why the numbness starts at the far ends and creeps inwards, symmetrically, in what doctors call a stocking-and-glove pattern. It is also why sensation goes before strength: the fibres that carry touch, vibration and position sense are more vulnerable than the ones that drive muscle. Weakness is not a normal part of this picture, and if it appears it needs to be looked at rather than accepted.
Tingling, numbness, burning and clumsiness with small objects are the expected pattern. Loss of grip strength, a foot that drags or one-sided symptoms are not, and warrant a review before the next cycle.
Toes before fingers, fingertips before palms, and both sides equally. Symptoms that climb steadily above the ankles or wrists are the ones that change the dose decision.
Neuropathy is cumulative rather than sudden. Little or nothing at cycle one, noticeable by cycle three or four, and most pronounced around the end of the course is the usual shape of it.
Chemotherapy-induced peripheral neuropathy is very common early and much less common later, and both halves of that sentence matter. A meta-analysis pooling more than four thousand patients across dozens of studies found nerve symptoms in roughly 68% of people in the first month after chemotherapy, 60% at three months and 30% at six months or more. So the majority of it does settle — and for around one in three it is still present half a year on. That gap is precisely why the dose and schedule decisions taken while you are still in treatment matter so much, and why reporting symptoms early is not fussing. Source: Seretny M et al., Pain (2014); ASCO Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy (2020).
Neuropathy has a fairly predictable shape across a course of ovarian cancer chemotherapy. Knowing that shape helps you tell the ordinary from the reportable, and saves a great deal of night-time worry.
Most women notice nothing during the first cycle or two. Somewhere around the third or fourth, the tips of the toes start to feel slightly distant, or the fingers tingle when holding a cold glass. It is easy to dismiss at this stage, and easy to attribute to sitting awkwardly or to the cold.
This early, mild stage is exactly when it is most useful to mention it. Nothing dramatic happens as a result — the team notes the grade and watches it — but it establishes a baseline, so that a change at the next cycle is obvious rather than debatable.
Women describe it in remarkably consistent ways: pins and needles, a buzzing or fizzing, fingers that feel as though they are wearing thin gloves, feet that feel padded or as if walking on thick socks. Fine touch fades first, so buttons, earring backs, coins and keys become fiddly before anything else does. Some people get the opposite of numbness — a burning or shooting pain, typically worse at night and worse when tired.
Two features are reassuringly typical: it is symmetrical, and it is worst at the far ends. Symptoms confined to one hand, or following a single line down one leg, are usually something else — a trapped nerve, a disc, or carpal tunnel syndrome — and should be described as such rather than filed under chemotherapy.
Taxane-class chemotherapy commonly causes a separate, short-lived problem that gets confused with neuropathy: a deep aching in the large muscles, hips, thighs, back and jaw, starting a day or two after the infusion and easing over the next several days. It is a recognised acute pain syndrome, it comes and goes with each cycle, and it does not by itself mean you are developing lasting nerve damage.
The difference is timing. The ache is tied to the infusion and settles before the next one. True neuropathy is quieter, sits in the fingers and toes rather than the big muscles, and does not clear between cycles — it accumulates. Describing which of the two you have, and when it happens in the cycle, tells your oncologist a great deal.
Platinum-class chemotherapy has an unsettling habit of continuing to cause symptoms after it has stopped. Numbness can plateau or even increase for some weeks after the final cycle before it begins to improve. This is called coasting, and it happens because the drug lingers in the sensory nerve cell bodies long after the infusions have finished.
It is worth knowing about in advance, because otherwise the timing feels alarming — treatment is over, and the symptom is getting worse. Coasting is expected behaviour rather than a new problem. It still deserves a mention at your follow-up visit, so that recovery can be tracked from a known peak.
Recovery is slow because nerve repair is slow. A damaged fibre regrows along its length at roughly a millimetre a day at best, and the fibres serving your feet are the better part of a metre long, so improvement is measured in months rather than weeks. Most women see steady improvement over the six to twelve months after treatment ends, often noticing it first in the fingers.
Some residual numbness persists in a minority, and the honest position is that nobody can predict at the outset which group you will be in. What is known is that severity at the end of treatment predicts what is left afterwards — which is the whole argument for adjusting the dose while treatment is still running. Day-to-day strategies for living with what remains are covered in our guide to living with chemo-induced neuropathy.
The strongest factor is simply cumulative dose — how much of the nerve-toxic classes you receive in total. Beyond that, nerves that are already compromised are less able to absorb the insult: diabetes, whether or not it has already caused symptoms, is the commonest example, followed by vitamin B12 deficiency, untreated thyroid disease and long-standing heavy alcohol use. Previous chemotherapy for an earlier cancer counts too.
None of these is a reason to avoid chemotherapy. They are reasons to say so before cycle one, so that baseline sensation is documented, B12 and thyroid are checked, diabetes is controlled properly through treatment, and the threshold for adjusting the dose is set lower from the start.
Numbness and tingling during chemotherapy is not automatically caused by chemotherapy. Diabetic neuropathy is extremely common in this age group and looks almost identical. Vitamin B12 deficiency, hypothyroidism and, in someone eating very little, other nutritional deficiencies all produce the same stocking-and-glove pattern. A simple blood panel settles most of it.
A few patterns point elsewhere and need prompt attention: symptoms on one side only, numbness in a band around the trunk, new weakness in the legs, or any change in bladder or bowel control. These do not fit chemotherapy neuropathy and should be reported the same day rather than at the next cycle.
Ovarian cancer treatment is not one drug, and the parts of it behave differently. This is the map of which element causes what, and what it typically feels like.
| Part of treatment | Effect on nerves | What you tend to notice |
|---|---|---|
| Taxane-class chemotherapy | Disrupts the internal transport scaffolding inside long nerve fibres, so the far ends run short of supplies. | Tingling and numbness in fingers and toes, often from the third cycle onwards, plus a separate deep muscle ache in the days after each infusion. |
| Platinum-class chemotherapy | Accumulates in the sensory nerve cell bodies alongside the spine, and clears from them slowly. | Numbness, loss of fine touch and reduced position sense; can keep worsening for weeks after the last cycle before improving. |
| The two given together (standard first line) | Effects on sensory nerves are additive, and cumulative across cycles. | The commonest pattern: symptoms that are mild early, clearly noticeable by mid-course, and most pronounced around the end of treatment. |
| Maintenance therapy (PARP-inhibitor class, anti-angiogenic class) | Peripheral nerve damage is not a typical effect of either class. | New or worsening numbness during maintenance is usually the earlier chemotherapy still settling, or a different cause entirely - worth investigating rather than assuming. |
| Causes unrelated to treatment | Diabetes, vitamin B12 deficiency, thyroid disease and heavy alcohol use damage the same nerve fibres. | Symptoms that pre-date chemotherapy, are one-sided, or follow the path of a single nerve. A blood panel and an examination separate these quickly. |
*Drug brand and molecule names are deliberately not used here, because the class is what determines the nerve effect. Which class you are on, at what dose and on what schedule is written on your chemotherapy chart — ask your medical oncologist to walk you through it, and see our guide to managing chemotherapy side effects in ovarian cancer.
Most of these are not emergencies. Each one, though, changes the decision your oncologist makes about the next dose — and that decision cannot be made retrospectively.
Symptoms spreading up the limb, rather than staying in the fingertips and toes, mark a step up in severity and usually prompt a change in dose.
Buttons, keys, coins and cups. Loss of fine hand function is a functional measure of severity and counts for more than how the numbness feels.
Burning or shooting pain at night is treatable in its own right and should not be endured quietly until the course finishes.
Unsteadiness in the dark, catching your foot on steps or reaching for walls means position sense is affected. Falls are the real risk here.
A foot that drags, a hand that cannot grip, or difficulty rising from a chair goes beyond the expected sensory pattern. Report it the same day.
Numbness on one side only, a band around the trunk, or new bladder or bowel changes do not fit chemotherapy neuropathy and need urgent assessment.
Tell the chemotherapy team before the next cycle, not at the end of the course. The response to neuropathy is a change in dose, schedule or drug class, and those levers only help while cycles remain. Nerve damage that is allowed to become severe is the kind most likely to persist. If you are between cycles and unsure, request a callback rather than waiting.
Bring your chemotherapy chart and the dates of your cycles. A 45-minute consultation is long enough to grade what you have, decide whether the dose or the schedule should change, and rule out the other causes of neuropathy that are common at the same age.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and takes 45 minutes. If your nerve symptoms warrant a dose change, we will say so; if they do not, we will explain why and what to watch for.
There is no drug that reliably repairs a damaged peripheral nerve. What works is adjusting the treatment that is causing the damage, and protecting function while nerves recover. This is the sequence.
Sensation, reflexes, grip and balance are checked, and you are asked what you can no longer do easily. Symptoms are scored on a standard toxicity scale so the trend across cycles is visible. This is why the question gets asked every time, and why a vague 'it is fine' costs you information you may need later.
The first and most effective lever is reducing the dose of the class responsible, usually the taxane-class component. Reducing a dose because of neuropathy is a planned part of the protocol, not a failure or a compromise on treatment, and it is done routinely in ovarian cancer chemotherapy.
Giving nerves a longer interval between doses allows partial recovery and can stop symptoms escalating. A week's delay changes very little about how the chemotherapy works against the cancer, and can change a great deal about what your hands feel like in a year.
Switching to a different administration schedule, substituting within a class, or completing the remaining cycles without the responsible drug are all options once enough treatment has been delivered. Where most of the planned course is complete, stopping the culprit early is sometimes the right call, and is a tumour-board conversation rather than a snap decision.
Ordinary painkillers work poorly on nerve pain. In ASCO's guideline the only medicine with a moderate-strength recommendation for painful chemotherapy-induced neuropathy belongs to the SNRI class of antidepressants, used here for its effect on nerve pain rather than for mood. Anti-seizure-class nerve-pain drugs are sometimes tried, on weaker evidence. Both need a proper prescription and review, not a pharmacy suggestion.
Physiotherapy for balance and gait, occupational therapy for hand function, and practical falls prevention at home matter more than most people expect — particularly with diabetes, where numb feet also need active foot care and daily inspection. Our guide to living with chemo-induced neuropathy covers the day-to-day of this.
*No supplement or vitamin has been shown to prevent chemotherapy neuropathy, and ASCO's guideline recommends none for prevention. One nutritional supplement widely promoted for nerve protection was tested in a randomised trial and left patients with more neuropathy, not less. Anything you are taking, including over-the-counter supplements, should be declared to your oncologist before the next cycle.
Neuropathy is the classic symptom that gets under-reported. It arrives gradually, it feels minor next to the cancer, and there is a widespread fear that mentioning it will lead to treatment being stopped. So women wait, and mention it at the end — which is the one point at which very little can be done. The point of a 45-minute consultation rather than a five-minute one is that there is time to ask the question properly and time for you to answer it honestly.
Chemotherapy for ovarian cancer is delivered by CION in-house, across more than 35 centres in Telangana and Andhra Pradesh, which means cycles, blood counts and the neuropathy check before each dose happen close to where you live rather than requiring a trip into the city every three weeks. Maintenance therapy, BRCA and HRD testing, genetic counselling, nutrition support and survivorship follow-up are in-house too. Dose decisions are made by the medical oncologist who is treating you, and anything that raises a question goes to a tumour board rather than to one clinician's judgement.
We are equally plain about what is not ours. Ovarian cancer surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there. If you are already on treatment elsewhere and want a second view on whether your dose should change, bring your chemotherapy chart and cycle dates to a free consultation — that, plus an examination, is usually enough for a clear answer, and it sits alongside the full picture of ovarian cancer treatment in Hyderabad.
Free, unhurried, and long enough to grade neuropathy properly, go through your chemotherapy chart and check the other causes of numbness that are common at the same age.
Neuropathy is assessed and scored at each visit rather than asked about in passing, so a change between cycles is documented and the dose decision rests on a trend.
Cycles and maintenance therapy are delivered by CION across 35+ centres in Telangana and Andhra Pradesh, which matters over a course that runs four to five months.
Chemotherapy, maintenance, genetic counselling and BRCA and HRD testing are ours. Surgery, HIPEC and PET-CT sit with partner centres, and we say so before you commit.
*Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are delivered by CION. Ovarian cancer surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres and may be billed there.
For most women it improves substantially, but slowly. Pooled data across many studies show nerve symptoms in roughly two-thirds of patients in the first month after chemotherapy, about 60% at three months and around 30% at six months or beyond. So the majority does settle, while a minority is left with something lasting, usually mild numbness in the toes. Recovery is slow because nerve fibres regrow at about a millimetre a day and the fibres serving your feet are close to a metre long, so progress is measured in months. Improvement often shows in the hands before the feet. The single strongest predictor of what remains is how severe the neuropathy was at the end of treatment, which is why reporting it early enough to adjust the dose matters more than anything taken afterwards.
Typically around the third or fourth cycle, though it varies. The first cycle or two usually pass without nerve symptoms because the effect is cumulative rather than immediate. It then builds gradually, is most noticeable towards the end of the course, and with platinum-class chemotherapy can continue to worsen for several weeks after the last cycle before it turns the corner. That late worsening is called coasting and is expected behaviour rather than a new problem. A separate and much earlier symptom is the deep aching in the large muscles and joints that some women get one to two days after a taxane-class infusion. That ache settles within a few days, returns with each cycle, and is a different phenomenon from the numbness in the fingers and toes.
No supplement or vitamin has been shown to prevent it, and ASCO's guideline recommends none for prevention. This is genuinely disappointing news that gets softened too often. One nutritional supplement widely promoted for nerve protection was tested in a randomised trial and left patients with more neuropathy rather than less, which is a useful reminder that untested does not mean harmless. Cooling gloves and compression during infusion have been studied, and the evidence is not yet strong enough to be recommended in guidelines. What genuinely helps is correcting things that damage nerves independently, such as low vitamin B12, untreated thyroid disease and poorly controlled diabetes, and adjusting the chemotherapy dose promptly when symptoms appear. Tell your oncologist about anything you are taking, including over-the-counter supplements, before your next cycle.
That is a judgement your medical oncologist makes with you, based on how severe the neuropathy is, how many cycles remain, and how the cancer is responding. Reducing the dose or spacing cycles is a routine, planned part of chemotherapy protocols rather than a failure, and it is the intervention that most reliably limits lasting damage. Stopping the responsible drug class while continuing the rest is another option, particularly when most of the planned course has already been delivered. What should not happen is silent endurance until the last cycle, because by then the levers that limit permanent damage are gone. Equally, do not stop or skip a cycle on your own. Report the symptoms, let them be graded, and have the conversation before the next dose is prescribed.
Nerve pain responds poorly to ordinary painkillers, which is why paracetamol and anti-inflammatories often disappoint here. In ASCO's guideline, the only medicine with a moderate-strength recommendation for painful chemotherapy-induced neuropathy belongs to the SNRI class of antidepressants, prescribed for its effect on nerve pain rather than for mood. Anti-seizure-class nerve-pain medicines are sometimes tried, on weaker evidence in this specific setting. Both need a proper prescription, a review of your other medicines and a few weeks to judge the effect. Alongside medication, simple measures do help: keeping feet cool and uncovered at night, loose bedding, gentle daily walking, and treating the sleep disruption itself. Tell your oncology team rather than managing it alone, because pain severe enough to disturb sleep is also information that should feed into your dose decision.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, with neuropathy graded before every cycle rather than asked about in passing. Genetic counselling, BRCA and HRD testing, nutrition support and survivorship follow-up are in-house as well. Ovarian cancer surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. If you are being treated elsewhere and want a second opinion on whether your dose should change, bring your chemotherapy chart and the dates of your cycles.